Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

[1]  L. Reiter,et al.  Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations , 2021, British journal of haematology.

[2]  E. Colado,et al.  Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. , 2021, The Lancet. Haematology.

[3]  Luca,et al.  Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis , 2021, Theranostics.

[4]  S. Corbetta,et al.  Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients , 2020, Mediators of inflammation.

[5]  M. Triggiani,et al.  Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification , 2020, Allergy.

[6]  M. Triggiani,et al.  International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. , 2019, The Lancet. Haematology.

[7]  T. Haferlach,et al.  MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Órfão,et al.  Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. , 2019, Blood.

[9]  M. Triggiani,et al.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.

[10]  P. Guglielmelli,et al.  Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. , 2018, Blood advances.

[11]  J. Lyons.  Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. , 2018, Immunology and allergy clinics of North America.

[12]  P. Valent,et al.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. , 2017, Blood.

[13]  G. Nilsson,et al.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. , 2017, Cancer research.

[14]  M. Triggiani,et al.  Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients , 2016, American journal of hematology.

[15]  T. Haferlach,et al.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.

[16]  S. Schoenberg,et al.  Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis , 2016, Leukemia.

[17]  M. Triggiani,et al.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis , 2015, Leukemia.

[18]  B. Sander,et al.  The presence of mast cell clonality in patients with unexplained anaphylaxis , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  P. Valent,et al.  The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease , 2014, Allergy.

[20]  A. Órfão,et al.  Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. , 2014, The Journal of allergy and clinical immunology.

[21]  G. Passalacqua,et al.  Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. , 2011, Bone.

[22]  C. E. Pedreira,et al.  Evaluation of the WHO criteria for the classification of patients with mastocytosis , 2011, Modern Pathology.

[23]  M. Chilosi,et al.  Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis , 2011, Haematologica.

[24]  A. Órfão,et al.  Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. , 2010, The Journal of allergy and clinical immunology.

[25]  A. Tefferi,et al.  WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.

[26]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[27]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[28]  G. Passalacqua,et al.  Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. , 2009, The Journal of allergy and clinical immunology.

[29]  L. Scott,et al.  Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. , 2007, Blood.

[30]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[31]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[32]  P. Valent,et al.  Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. , 2004, The Journal of allergy and clinical immunology.

[33]  M. Fiegl,et al.  Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease , 2002, International Archives of Allergy and Immunology.

[34]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[35]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[36]  J. Bernhard,et al.  Mastocytosis , 1997, The Lancet.

[37]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.